Expertise in
3
conditions

Dr. Jerry H. Bagel

Sdg Dermatology PC
East Windsor, NJ
Expertise in
3
conditions
Specialties:Dermatology
Accepting New Patients
Expertise in
3
conditions
OverviewInsuranceLocationsClinical Research

Overview

Jerry Bagel is a Dermatologist in East Windsor, New Jersey. Mr. Bagel is highly rated in 3 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Infectious Myocarditis. Mr. Bagel is currently accepting new patients.

His clinical research consists of co-authoring 89 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in NJ
Languages Spoken
English
Italian
Spanish
Yiddish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

SDG DERMATOLOGY PC
59 One Mile Rd Ext, Suite B, East Windsor, NJ 08520
609-443-4500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis
A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: April 16, 2024
Intervention Type: Drug
Study Drug: Otezla
Study Phase: Phase 4
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: June 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers
An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers
Enrollment Status: Completed
Publish Date: March 11, 2020
Intervention Type: Drug
View 10 Less Clinical Trials

89 Total Publications

Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Journal: Current medical research and opinion
Published: December 03, 2024
Similar Doctors
Victoria P. Werth
Expertise in
29
conditions
Dr. Victoria P. Werth
Dermatology
Expertise in
29
conditions
Dr. Victoria P. Werth
Dermatology

Penn Dermatology Perelman

3400 Civic Center Boulevard, Perelman Center For Advanced Medicine,South Pavilion, 1st Floor, 
Philadelphia, PA 
 (40.9 mi)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Victoria Werth, MD is a Dermatologist in Philadelphia, PA and has over 42 years of experience in the medical field. She graduated from Johns Hopkins School of Medicine in 1980. She is affiliated with Hospital of the University of Pennsylvania. Dr. Werth is highly rated in 29 conditions, according to our data. Her top areas of expertise are Cutaneous Lupus Erythematosus (CLE), Dermatomyositis, Discoid Lupus Erythematosus (DLE), and Pemphigus.

Expertise in
31
conditions
Dr. Mark G. Lebwohl
Dermatology
Expertise in
31
conditions
Dr. Mark G. Lebwohl
Dermatology
5 E 98th St, 5th Floor Box 1048, 
New York, NY 
 (47.3 mi)
212-241-5778
Languages Spoken:
English

Mark Lebwohl is a Dermatologist in New York, New York. Dr. Lebwohl is highly rated in 31 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Pustules.

Expertise in
24
conditions
Dr. Alice B. Gottlieb
Dermatology | Rheumatology
Expertise in
24
conditions
Dr. Alice B. Gottlieb
Dermatology | Rheumatology

Mount Sinai Downtown-Union Square

10 Union Square East, 3c, 
New York, NY 
 (43.2 mi)
212-844-8800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alice Gottlieb is a Dermatologist and a Rheumatologist in New York, New York. Dr. Gottlieb is highly rated in 24 conditions, according to our data. Her top areas of expertise are Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, and Arthritis. Dr. Gottlieb is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile